INOVIO PHARMACEUTICALS, INC.
INO-3107
Recurrent Respiratory Papillomatosis (RRP)
Countdown
116days
FDA decision · Oct 30, 2026
What's at stake
The FDA's approval decision on INO-3107 for Recurrent Respiratory Papillomatosis (RRP) is due Oct 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“target Prescription Drug User Fee Act (PDUFA ) date October 30, 2026”